Post by
prophetoffactz on Jul 15, 2024 11:39am
HC Wainwright
Perplexity Ai:
"H.C. Wainwright set its $15 price target for Aeterna Zentaris (NASDAQ:AEZS) on November 13, 2023. This new target was actually a downward revision from their previous price target of $28. Despite lowering the price target, H.C. Wainwright analyst Raghuram Selvaraju maintained a "Buy" rating on the stock."
H.C. Wainwright adjusted that target price essentially
at the bottom of the biotech bear market. The S&P
biotech ETF is up over 48% since the day the new
target was set of US$15 or C$100 market cap.
Assuming the same beta despite AEZS being a
microcap would mean a C$148 million market cap
target or C$38 for current shareholders. While
H.C. Wainwright may have lowered its target based on
fundamentals given the merger of equals AEZS
may have doubled its asset value given it now has
CZO's assets. The diagnostic trial results and a deal
will also bring enhanced clarity to what the diagnostic may be
worth. Gilles was on the Board of Directors of AEZS
and has an inside scoop concerning the value of
potential deals as a deal was anticipated based on outreach.